



Eureka-Singapore

Monsoon Certificate Course in Translational Medicine

14 – 18 November 2022

One°15 Marina Club, Sentosa, Singapore

Organised By:



In Partnership With:



Name:

“Translational Medicine (TM) is defined as the resolution of unmet medical needs through the use of technology, creativity and scientific method. The field of translational medicine encompasses molecular medicine, intellectual property, financing, regulation, preclinical and clinical trial studies, among other disciplines.”

Unlike traditional courses, the Eureka Monsoon Certificate Course in Translational Medicine (MCC) is tailored to individual needs. Expect five days of complete seclusion from work and an intense experience with the expert faculty members. MCC is not solely based on lectures but on learner-centred discussions, mentoring by internationally recognised leaders, and exploration of real-life case studies. Skills garnered from this programme will help individuals and team members to address the challenges facing drug development today and bridge the divide between concept and patient.

The MCC is targeted at researchers interested in translational research and looking to further expand their skill sets or individual career development, be it in research, academia and/or industry.

Participants can expect to:

- Analyse the business, scientific and regulatory aspects of TM, and develop critical-thinking skills to approach and explore the challenges
- Examine case studies, and develop creative problem-solving strategies and novel skills to build new kinds of teams
- Hone their abilities to communicate effectively across broad audiences
- Be inducted into the Eureka Network upon graduation – having direct access to a vast network of accomplished peers, leaders and partners in TM – all building bridges and closing gaps to form a global community of TM professionals

ABOUT EUREKA

The vision of the Eureka Institute for Translational Medicine (Eureka) is to develop translational medicine to address unmet medical needs. More specifically, Eureka’s mission is to build and foster a global community of translational medicine professionals to advance the application of biomedical innovation for the tangible benefit of patients and society as a whole.

Eureka is a not-for-profit institute founded by an international group of leaders in translational medicine. Eureka’s overall strategy is to catalyse, integrate and impact education, research and policy-making in an international translational medicine ecosystem that benefits society. The institute does this through education and building a community of translational scientists.

Among the activities of Eureka are an annual International Certificate Course in Translational Medicine in Siracusa, Italy.

Eureka partners with major universities worldwide: SingHealth Duke-NUS Academic Medical Centre, Stanford Maternal & Child Health Research Institute, Bocconi University, Drexel University, National Foundation of Emergency Medicine, University of Catania, University of Miami, University of Arizona, University of Toronto, Università Vita Salute San Raffaele, United Arab Emirates University and the UMC Utrecht. Nutricia Research, Parent Project Muscular Dystrophy, Nature Research and University College London are also supporters of Eureka (www.eurekainstitute.org).

Edited and Compiled by The Eureka Institute for Translational Medicine

A publication of the Eureka Institute for Translational Medicine. Prepared in the partial fulfillments of the requirements for the certification of completion. Continuing Medical Education credits are not being offered. Course materials and handouts include edited and compiled works of multiple authors.

Copying material contained in this document or other course materials for general distribution, for advertising or promotional purposes, for resale, for creating new collective works, or for commercial proprietary purposes, is strictly prohibited.

Requests for reprints or reproduction to:

Eureka Institute for Translational Medicine
Benjamin Lim
c/o TII, The Academia, Ngee Ann Kongsi Discovery Tower
Level 8, 20 College Road, Singapore 169856
info@eurekainstitute.org

© 2022 Eureka Institute for Translational Medicine
All Rights Reserved

Dear Participants

The Monsoon Certificate Course is an initiative that is part of the partnership between SingHealth Duke-NUS Academic Medical Centre and the Eureka Institute for Translational Medicine.

Our mission, which we are profoundly committed to, is to change Medicine by harnessing technology to address unmet medical needs. Our Ethos is “patients at the heart of all we do”. With this in our hearts and minds, we aim to be transformational locally, regionally and worldwide, by inspiring and catalysing growth through innovation, education through experience, and transformation through creativity and resilience. A major goal of our Academic partnership is transforming medicine and improving lives. Truly durable and meaningful transformation requires people as its foundation. We are proud to contribute, through this Monsoon Certificate Course, to the formation of the leaders of the future: YOU.

We welcome you with open arms and a warm smile for an exciting journey together.

Professor Ivy Ng
Group CEO
SingHealth



Professor Thomas Coffman
Dean
Duke-NUS Medical School



Dear Participants

It is my greatest pleasure and honour to welcome you to the Eureka-Singapore Monsoon Certificate Course in Translational Medicine (MCC), organised with the SingHealth Duke-NUS Academic Medical Centre. Translational Medicine faces many challenges and the only way to solve this definitely is to work together and find new solutions for the pressing problems we face. Eureka was founded over a decade ago to do just that, and to empower young translational scientists to overcome the many hurdles between bench and bedside.

Already it has become clear that many of the most promising new advancements and opportunities in TM sprout from this part of the world. As an example, SingHealth Duke-NUS Academic Medical Centre has been one of the first partners and promoters of Eureka. It is clear that Asia will play a pivotal role in the future of translational medicine. This course offers you all possibilities to explore and find your own personal role in this exciting field. A line up of experienced and innovative leaders in translational medicine is ready to help you to take the next steps in your career. I am confident that this course will offer everything you need to become a successful translational researcher.

I wish you an inspiring meeting!

Berent Prakken
Vice-dean Education & Director of the Biomedical Education Center;
Professor of Paediatric Immunology, University Medical Center Utrecht;
Co-Founder, Eureka Institute



ABOUT SINGHEALTH DUKE-NUS ACADEMIC MEDICAL CENTRE

The strategic partnership in Academic Medicine between Singapore Health Services and Duke-NUS Medical School builds on the collective strengths of the SingHealth Group and Duke-NUS' research and medical education capabilities. Together, they create a vibrant academic nexus for new discoveries, learning and care innovation – and bring it to where it matters most: Patients. The Academic Medicine efforts are enhanced with the establishment of the Academic Clinical Programmes (ACPs) and joint institutes, including the Academic Medicine Education Institute (AMEI) and Academic Medicine Research Institute (AMRI) which facilitate the active growth and development of driven scientists and educators into the SingHealth Duke-NUS family (<https://www.singhealthdukenus.com.sg/>).

Speaker list 2022

Salvatore Albani, MD, PhD,

Professor, Duke-NUS Medical School, Singapore;
 Director, Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre;
 Senior Consultant, KK Women's and Children's Hospital;
 President, Eureka Institute for Translational Medicine

Scott Compton, PhD

Professor & Associate Dean for Medical Education; Duke-NUS Medical School, Singapore;
 Programme Director, Master of International Translational Medicine, Duke-NUS Medical School, Singapore;
 Member, Eureka Institute for Translational Medicine;
 Co-Director, Monsoon Certificate Course

Muhammad Raihan Jumat, PhD, Fellow (HEA)

Assistant Professor, Duke-NUS Medical School;
 Co-Director, Monsoon Certificate Course

Adrian Lim, BCom/LLB, MBA

CEO, Biotech startup (in stealth);
 Co-Founder, SimPharma

Ann-Marie Chacko, PhD

Assistant Professor, Cancer & Stem Cell Biology Programme;
 Head, Laboratory for Translational and Molecular Imaging (LTMI);
 Co-Lead, Cancer ImmunoTherapy Imaging (CITI) Programme, Duke-NUS Medical School, Singapore

Ang Hwee Ching, PhD

Deputy Chief Executive Officer, Experimental Drug Development Centre

Berent Prakken, MD, PhD

Vice-dean Education and Director of the Biomedical Education Center;
 Professor of Paediatric Immunology, University Medical Center Utrecht;
 Co-Founder, Eureka Institute for Translational Medicine

Chriscavin Wijaya

Full-time Student

Danny Soon, MBBS

Chief Executive Officer, Consortium for Clinical Research and Innovation Singapore;
 Executive Director, Singapore Clinical Research Institute

David Wang Xinyuan, MD, MBA

Director, Centre of Technology and Development Office of Innovation and Entrepreneurship, Duke-NUS Medical School, Singapore

Derrick Chan, BMedSci, BMBS, MCI, MRCPCH, CSCN, FAMS

Senior Consultant, KK Women's and Children's Hospital;
 Principal Lead Mentor – Clinician Innovator Development Programme (CINDP), CCSD;
 Programme Director - CINDP, Academic Development Department, Duke-NUS Medical, Singapore
 Lead (Culture Building and Developing Human Capital), Academic Medicine Innovation Institute;
 Director, SingHealth MedTech Office

Enny Kiesworo, BSc (Pharmacy), MHA, MSc (HPPF)

Group Director, Research (Corporate Admin and Technology Development), SingHealth

Francesco Caruso, LL.M, MSc

CEO, Firetree advisory Pte. Ltd;
 Protector, Firetree Trust;
 Co-Founder & Director, Asia Community Foundation Limited;
 Member, Asia Philanthropy Circle.

Joanne Ngeow Yuen Yie, MBBS (Melb), MMed, FRCP (UK), FAMS, MPH

Head, Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre Singapore;
 Associate Professor, Lee Kong Chian School of Medicine, Nanyang Technological University

John C W Lim, MBBS, MSc, SM

Professor & Executive Director, Centre of Regulatory Excellence, Duke-NUS Medical School;
 Chairman, Consortium for Clinical Research & Innovation Singapore;
 Senior Advisor, Ministry of Health, Singapore;
 Policy Core Lead, SingHealth Duke-NUS Global Health Institute

Mara McAdams, MD

Assistant Professor, Duke-NUS Medical School, Singapore;
 Associate Dean, Alumni Relations, Duke-NUS Medical School, Singapore

Ng Chirk Jenn, MBBS, MMed (Family Medicine), PhD

Clinical Professor, Duke-NUS Medical School, Singapore;
 Senior Consultant, SingHealth Polyclinics

Ronne Yeo, PhD

Managing Director, EVX Ventures Pte Ltd;
 Cofounder and Chief Scientific Officer, Carcell Therapeutics Pte Ltd

Sarada Bulchand, PhD

Assistant Professor, Academic Medicine Education Institute, Duke-NUS Medical School;
 Lead, Duke-NUS Career Development Programme

Soo Khee Chee, MBBS, MD, FRACS, FACS, FAMS

Founder, Soo Khee Chee Surgery;
 Professor, Duke-NUS Medical School, Singapore;
 Visiting Consultant, National Cancer Centre Singapore (NCCS)

Toh Han Chong, BSc (London), MBBChir (Camb), MRCP (UK), FRCP(Edin) FAMS

Deputy Chief Executive Officer (Strategic Partnerships), NCCS
 Senior Consultant, Division of Medical Oncology, NCCS

Valerie Chew Suk Peng, PhD

Assistant Professor, Duke-NUS Medical School;
 Principal Investigator, Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre

Wang Linfa, PhD

Professor, Programme in Emerging Infectious Diseases, Duke-NUS Medical School;
 Executive Director, Programme for Research in Epidemic Preparedness and Responses (PREPARE)

Wong Tien Yin, MBBS, MMED, MPH, PHD, FRCSE, FRANZCO, FRCOPHT, FAHMS, FAMS

Founding Head and Chair Professor, Tsinghua Medicine, Tsinghua University;
 Senior Advisor, SingHealth & Singapore National Eye Centre

Yeo Joo Guan, MBBS (S'pore), MMed (S'pore), MRCPCh (UK), PhD (S'pore)

Vice Chair (Research), SingHealth Duke-NUS Paediatrics Academic Clinical Programme;
 Senior Consultant, Division of Medicine, KK Women's and Children's Hospital;
 Clinician-Scientist, Translational Immunology Institute (TII), SingHealth Duke-NUS Academic Medical Centre

Organisers

Eureka Institute for Translational Medicine
www.eurekainstitute.org

Organising Committee

Salvatore Albani
 Scott Compton
 Raihan Jumat

In Partnership with:

SingHealth Duke-NUS Academic Medical Centre
<https://www.singhealthdukenus.com.sg>

Course Coordination

Benjamin Lim, +65 9730 9311

Experimental Drug Development Centre (Singapore)

Course Venue

NOVA Room
 One°15 Marina Club
 11 Cove Drive, Sentosa Cove, Singapore 098497
<http://one15marina.com>



How to get there

1. By One°15 Marina shuttle bus (see instruction provided in the following)
2. By Car

By One°15 Marina shuttle bus

1. Shuttle bus pick up point is from Harbourfront MRT Station Exit D taxi stand. Please see below schedule.
2. Upon alighting, turn right and walk along the brick pathway to the clubhouse.
3. Once entering the clubhouse, proceed to the lobby where there will be signs pointing you to the event's venue.

Shuttle operating schedule to One°15 Marina	
From Harbourfront MRT Station Exit D taxi stand (Mon-Fri)	
	07:00
	07:45
	08:10
	08:30
From One°15 Marina to Harbourfront MRT Station	
	18:10
	18:30
	19:15
	19:45



Important note:

Pre-arranged transport IN and OUT of One°15 Marina is provided at stipulated timings only. Kindly arrange your own transport at own cost, if you miss it.

Eureka Dynamic Sessions

A significant element of the programme is going to involve YOU talking, either one-to-one or in small groups. The aim of all these sessions is to help you to learn from each other and the faculty directly, and to focus on those parts of translational medicine, and a career in translational medicine, that matter most to you.

The Magic Bullet

This case examines the full translational tightrope of a targeted therapy, from lead identification to Phase II and III clinical trials. You will work in depth with the case in a pre-allocated small-group setting over three separate sessions (Wednesday, Thursday and Friday).

Through this case, you'll grapple with the development of a therapy intended for a targeted sub-population, and explore the issues arising in the post-market phase. In addition, you will discuss and determine research and business strategies necessary to "translate" a potential therapeutic and co-develop its companion biomarker. Parallel concepts of collaboration and team will also be explored.

Recommended Reading:

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med.* 2001 Mar 15;344(11):783-92. PMID: 11248153. Available at <http://www.nejm.org/doi/full/10.1056/NEJM200103153441101>

Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer, *J Clin Oncol.* 2009 Dec 1;27(34):5838-47. Epub 2009 Nov 2. Review. PMID: 19884552

Speed Consulting

"Speed Consulting" provides the opportunity for you to have a series of one-on-one discussions with individual faculty for 10 minutes each. Who you talk with and on what topics are your choices!

Please consult the faculty biographies in this booklet prior to completing the signup sheet, which will be prominently displayed and made available from Monday.

There will be two sessions: Tuesday and Thursdays late afternoons.

For some sessions, you will be allocated to a specific group (The Magic Bullet; Mentoring; Presentations). For Speed Consulting, you will choose who you want to meet and/or which topic you want to discuss (see p.48-49 for the group allocations).



Mentoring

You will each present a dilemma you are currently facing to a small group of peers. You will be allocated to a group, which will be mentored by a faculty member. Your fellow course participants will act as a consultation group. The objective is to advance personal learning while practising and improving approaches to, and organisation of, problem solving.

Reflections using practical real-world problems will anchor the concepts raised in the didactic portion of the programme.

As some of you already know, work with or have worked with some of the faculty members, every effort will be made to ensure you have "neutral" tutors guiding the sessions. In addition, unless otherwise specified and agreed to by the group, discussions in the mentoring session are treated as confidential.

You will have your first session on Thursday morning, then come back together on Friday morning.

Raising Your Communication Game

The Eureka Presentation Workshop


Communication is not something you add on to science; it is the essence of science.

- Alan Alda

Bad presentations are a contagion, spread by fear and lack of preparation. In this session, we discuss unusual and effective techniques for engaging in clear scientific communication, using techniques gleaned from the TED talks series, from the Alan Alda Center for Communicating Science at Stonybrook University, and the experience of our mentors and instructors. Goals of this interactive and experiential session are to raise each presenter's speaking game, with improved audience awareness and focus, including a focus on tailoring communication style to the audience and predictable, high audience engagement.

In addition to a brief introductory session focused on general concepts of excellent scientific communication, this session will involve TED-talk type presentations by each participant in a small group setting. Each presentation will be recorded. After the presentation, the speaker will then review her/his own tape in private. During this time, the group will prepare constructive feedback for the presenter. Afterward, the group gets back together to hear the presenter's own reflections and provide feedback intended to further raise that presenter's game.

For those interested, tips on giving feedback are provided in the material for this session.



Feedback Tips

Definition

The process of giving data back to the participant for the purpose of bringing about change.

Feedback involves responding specifically to an event or occurrence, whether that event be good or bad. Positive and negative feedback should be distinguished from complimenting and criticising.

Evaluation is an assessment of a learner's achievement and/or performance.

1. Feedback should be undertaken with the observer and participant working as allies with common goals. Begin by discussing respective expectations.
2. Feedback should be descriptive rather than evaluative.
3. Feedback should deal with specific events, rather than generalisations.
4. Feedback should be well-timed, and expected, in close proximity to the event, but not when – the recipient is post-call or angry about the issue; facts are missing; or both sides of the situation have not been explored.
5. Feedback should be based on first-hand data.
6. Feedback should be focused on behaviours that are amenable to change.
7. Feedback should involve sharing of information, rather than giving advice, leaving the receiver free to decide for themselves in accordance with their own goals and needs.
8. Feedback can be structured to include subjective data, as long as it is clearly labeled as such.
9. Feedback should be checked to insure clear communication by having the receiver try to rephrase the feedback.
10. Feedback should be followed by attention to the consequences of feedback.

Taking the Plunge

1. Be clear about the purpose of the feedback session.
2. Get the receiver's perspective as to how things are going.
3. The sandwich technique (i.e., good / bad / good) isn't always reliable.
4. Ask the recipient to offer solutions.
5. Develop solutions to the problem, and a plan to improve the situation.



Course Schedule



Monday, 14th November 2022

Time	Title & Speakers
08:30-09:00	Registration
09:00-10:00	Introductions Speakers: Raihan Jumat & Scott Compton
10:00-10:15	Break
10:15-11:15	Translational Medicine Overview Speaker: Salvatore Albani
11:15-12:15	Patient and Society Speakers: Toh Han Chong & Chriscavin Wijaya Abstract Childhood cancer survivors often go through different challenges in their cancer treatment journey. One of their challenges is coping with treatment and its side effects. This session will shed light on a childhood cancer survivor's journey with treatment and how it changed his life. It is important for medical professionals to understand how cancer treatment affects patients' lives so that we can better support them through this journey.
12:15-13:30	Buffet Lunch @ Bar Nebula Level 1
13:30-14:30	Digital Health Speaker: Ng Chirk Jenn
14:30-15:30	PREPARE Speaker: Wang Linfa
15:30-15:45	Break
15:45-17:45	Culturally Competent Communication - Part 1 Speakers: Mara McAdams, Sarada Bulchand & Scott Compton
17:45	Day Ends

Tuesday, 15th November 2022

Time	Title & Speakers
08:30-09:00	De-Briefing: What can you bring home? Speaker: Raihan Jumat
09:00-11:15 (With 15 mins break)	Drug Development Speaker: Salvatore Albani
11:15-12:15	Culturally Competent Communication - Part 2 Speakers: Mara McAdams, Sarada Bulchand & Scott Compton
12:15-13:30	Set Lunch @ Latitude Bistro
13:30-14:30	<p>Communication: Self-Awareness & Self Management Speakers: Sarada Bulchand & Mara McAdams</p> <p>Abstract</p> <p>Assumptions are an efficiency of the brain. We see patterns and come to conclusions. However, assumptions can also create bias and limit our perspectives on a situation and hence the decisions we make. There are proven strategies for managing assumptions that can be used to enhance resourcefulness.</p> <p>Learning Objectives</p> <ol style="list-style-type: none"> 1. Identify your own assumptions 2. Reflect on self-expectations <p>Preparation</p> <ol style="list-style-type: none"> 1. Emotional Intelligence Skills: What they are and how to develop them (HBS Online Blog) by Lauren Landry Blog https://online.hbs.edu/blog/post/emotional-intelligence-skills (This will take about 10 minutes.) 2. Be ready to share your reflection on the Thought Question below. <p>Pre-Session Thought Questions for Participants</p> <p>The HBS Online article lists five Emotional Intelligence skills that leaders need to be successful -- self-awareness, self-regulation, empathy, motivation, and social skills. Which one is your strength?</p>
14:30-15:30	<p>Presentation Workshop See p.6 on Eureka Dynamic sessions for details</p> <p>Facilitators</p> <ul style="list-style-type: none"> • Ann-Marie Chacko • Raihan Jumat • Salvatore Albani • Sarada Bulchand • Scott Compton • Yeo Joo Guan

Tuesday, 15th November 2022 (Continued)

Time	Title & Speakers
15:30-15:45	Break
15:45-16:45	<p>Communication: Communication: Relationship Management Speakers: Sarada Bulchand & Mara McAdams</p> <p>Abstract</p> <p>Conflict is healthy and integral to optimal individual and team performance. There are five styles for conflict management, and each of us has one or two that we prefer. Knowing all the styles and when to use them gives leaders more options for effectively managing conflict.</p> <p>Learning Objectives</p> <ol style="list-style-type: none"> 1. Increase self-awareness of your conflict management style 2. Appreciate the utility of each conflict style <p>Preparation</p> <ol style="list-style-type: none"> 1. Read the short handout titled Healthy Conflict which was previously sent in email (This will take about 5 minutes.) 2. Please take this conflict management self-assessment. It is a 35 question assessment. (This will take you 10-12 minutes) Please respond based on what is true for you most of the time. Scroll down this site to see the questions. https://psycho-tests.com/test/conflict-mode Please report the results of your self-assessment, in this form https://forms.office.com/r/8GcFNp4EYZ . The name list will not be shared with the class, but anonymised results will be shown. 3. Be ready to share your reflection on the Thought Question below. <p>Pre-Session Thought Questions for Participants</p> <p>Reflect on a recent conflict or tension you had (this can be just a small disagreement not a full-on fight!). What was your approach to the conflict?</p>
16:45-17:45	<p>Speed Consulting 1 See p.5 on Eureka Dynamic sessions for details</p> <p>Faculty</p> <ul style="list-style-type: none"> • Ann-Marie Chacko • Derrick Chan Wei Shih • Joanne Ngeow Yuen Yie • Raihan Jumat • Salvatore Albani • Sarada Bulchand • Scott Compton • Yeo Joo Guan
17:45	Day Ends

Wednesday, 16th November 2022

Time	Title & Speakers
08:30-09:00	De-briefing - What can you bring home? Speaker: Raihan Jumat
09:00-11:15 (With 15 mins break)	The Foundation and the future of Clinical Development Speakers: Danny Soon & John CW Lim
11:15-12:15	Finding a New Equilibrium Speakers: Sarada Bulchand & Mara McAdams Abstract Finding a new equilibrium entails better self-awareness of our assumptions, preferences and biases so that we can intentionally reframe, take perspective, and then make a choice of how best to proceed. When it comes to a challenging conversation, you can draw on strategies to best prepare yourself, and you can apply self-compassion when the outcomes doesn't meet your expectations. Learning Objectives 1.Develop strategies to manage expectations 2.Practice self-compassion Preparation 1.Bring your notes from Session 1 (Reality and Expectation circles) 2.Be ready to share your reflection on the Thought Question below. Pre-Session Thought Questions for Participants In what ways am I more self-critical than self-compassionate?
12:15-14:30	Buffet Lunch @ Bar Nebula Level 1
14:30-15:30	Magic Bullet (1/3) See p.5 on Eureka Dynamic sessions for details Faculty • Ann-Marie Chacko • Raihan Jumat • Salvatore Albani • Sarada Bulchand / Yeo Joo Guan • Scott Compton
15:30-15:45	Break
15:45-16:45	Career Trajectory Dissection (Remote Session) Speaker: Berent Prakken
16:45-17:45	SG Startup Enterprise Speakers: Adrian Lim, Salvatore Albani & Ang Hwee Ching
17:45	Day Ends

Thursday, 17th November 2022

Time	Title & Speakers
09:45-10:15	<p>De-briefing: What can you bring home? Speaker: Raihan Jumat</p>
10:15-11:15	<p>Philanthropic Funding Speaker: Francesco Caruso</p> <p>Abstract</p> <p>Venture philanthropy sees charitable givings as investments and draws on the analytical rigour of the for-profit world to assess the non-profit organisations that it supports. The primary performance metric is the impact that the funding given will create, where impact is the change that happens because of the activities funded, that would have not happened otherwise.</p> <p>The 'World of philanthropy' is composed by very different types of funders, which use several different tools to finance the development of solutions aimed to achieve impact. Philanthropists decide who and what to fund based on their assessment of risk vs opportunity of success.</p> <p>This session will discuss the type of philanthropic funders, their financing tools and the way different philanthropists assess risk and thus decide who they shall fund and/or invest in.</p> <p>Learning Objectives</p> <ol style="list-style-type: none"> 1.Understand how philanthropic investors assess and mitigate risk; 2.Identify most suitable sources of philanthropic financing for the specific activity/phase of development they are seeking funds for. <p>Preparation (Reading Materials)</p> <ol style="list-style-type: none"> 1.https://ssir.org/articles/entry/innovating_philanthropy 2.https://buildingimpact.co/blog/5-ways-to-embrace-risk-in-philanthropy-for-more-impact-and-greater-fulfillment-blog/ <p>Pre-Session Thought Questions for Participants What do you think the role of philanthropy is and/or should be in the Translational Medicine continuum?</p>

Thursday, 17th November 2022 (Continued)

11:15-12:15	Mentoring Session 1 See p.5 on Eureka Dynamic sessions for details Mentors <ul style="list-style-type: none">• Ann-Marie Chacko• Enny Kiesworo• Raihan Jumat• Salvatore Albani• Soo Khee Chee• Yeo Joo Guan
12:15-13:30	Set Lunch @ Latitude Bistro
13:30-14:30	Impactful Venture Speaker: Arcot Desai Narasimhalu
14:30-15:30	Magic Bullet (2/3) See p.5 on Eureka Dynamic sessions for details Faculty <ul style="list-style-type: none">• Ann-Marie Chacko• Raihan Jumat• Salvatore Albani• Sarada Bulchand / Yeo Joo Guan• Scott Compton
15:30-15:45	Break



Thursday, 17th November 2022 (Continued)

15:45-16:45 **Inequalities & Inequities in Healthcare & Science**
Speakers: Ann-Marie Chacko & Valerie Chew Suk Peng

Abstract:

Despite the understood necessity as a matter of science and ethics, the underrepresentation of sex, gender, ethnic, and racial minorities in drug development, and in clinical research more generally, still persists. Further, these disparities impact diversity in research and innovation, as well as career opportunities and growth, including impact on salaries, funding, entrepreneurship, and leadership

Learning Objectives:

This session aims to share experiences, dissect views and opinions such that by the end of this session, participants will be able to:

1. Identify and address health disparities in clinical research and in science, particularly in academic leadership and entrepreneurship.
2. Identify approaches that can be implemented to integrate the different dimensions of diversity to address health inequalities and inequities.

Preparation (Reading Materials):

1. The fraught quest to account for sex in biology research (2022 Nature News Feature).
<https://www.nature.com/articles/d41586-022-02919-x>
2. Historical comparison of gender inequality in scientific careers across countries and disciplines (PNAS 2020).
<https://www.pnas.org/content/117/9/4609>
3. Gender in the Global Research Landscape (Elsevier Report 2017)
https://www.elsevier.com/_data/assets/pdf_file/0008/265661/ElsevierGenderReport_final_for-web.pdf
4. Systemic racism persists in the sciences (Science 2020).
<https://science.sciencemag.org/content/369/6502/351>

Pre-Session Thought Questions for Participants

1. What type of experiences have you faced in your career based on disparities in healthcare?
2. Do you have any suggestions on how to overcome the disparities in healthcare and science?

16:45-17:45 **Speed Consulting 2**
See p.5 on Eureka Dynamic sessions for details

Faculty

- Ann-Marie Chacko
- Derrick Chan Wei Shih
- Raihan Jumat
- Salvatore Albani
- Sarada Bulchand
- Scott Compton
- Yeo Joo Guan

17:45 **Day Ends**

Friday, 18th November 2022

Time	Title & Speakers
08:30-09:00	De-briefing - What can you bring home? Speaker: Raihan Jumat
09:00-10:00	Journey into the future Speaker: Ronne Yeo
10:00-10:15	Break
10:15-11:15	Mentoring Session 2 See p.5 on Eureka Dynamic sessions for details Mentors <ul style="list-style-type: none"> • Ann-Marie Chacko • Enny Kiesworo • Raihan Jumat • Salvatore Albani • Soo Khee Chee • Yeo Joo Guan
11:15-12:15	Protecting Intellectual Property Speaker: David Wang Xinyuan Abstract Intellectual property (IP) plays an essential role in both the research and teaching functions of universities and research institutes. Through their R&D and teaching activities, universities and research institutes produce results in the form of inventions, scholarly publications, databases, confidential information, computer programs, etc. Many of these can be protected by IP. This session will make an introduction to IP and IP rights, and will discuss how to protect IP. Learning Objectives <ol style="list-style-type: none"> 1.Understand IP and IP rights 2.Understand IP ownership 3.Learn how to protect IP Preparation (Reading Materials) <ol style="list-style-type: none"> 1.https://www.ipos.gov.sg/about-ip Pre-Session Thought Questions for Participants <ol style="list-style-type: none"> 1.What is IP? 2.Who owns it? 3.How to protect IP? 4.What's the difference between authors in publications vs inventors in patents?
12:15-13:30	Lunch @ Wok 15

Friday, 18th November 2022 (Continued)


Time	Title & Speakers
13:30-14:30	<p>Magic Bullet (3/3) See p.5 on Eureka Dynamic sessions for details</p> <p>Faculty</p> <ul style="list-style-type: none"> • Ann-Marie Chacko • Raihan Jumat • Salvatore Albani • Scott Compton • Yeo Joo Guan
14:30-15:30	<p>Being an Eurekaian - How to make an impact as an Eurekaian? Speakers: Ann-Marie Chacko & Yeo Joo Guan</p> <p>Abstract</p> <p>Over 1,000 people from over 35 countries and all continents have attended at least one Eureka's event and are now part of the Eureka Network. The Eureka network, which comprises all TM stakeholders (patients, scientists, clinicians, research institutes, funding agencies, biotech startups, industries, investors, regulatory authorities, and decision-makers), is a fertile ground for the generation of a healthy ecosystem and innovative initiatives. In this session, we will present the current "Eureka Impact" priorities for the network and highlight how you can contribute to the success of the Eurekaian mission.</p> <p>Learning Objectives:</p> <ol style="list-style-type: none"> 1. Identify how your personal Eurekaian experience can impact your TM network. 2. Develop strategies and actions to create a proactive community of Eurekaians and know its transformative power. <p>Pre-session Thought Questions for Participants:</p> <ol style="list-style-type: none"> 1. What do you hope to gain from attending Eureka Monsoon Certificate Course? 2. What can you offer to the Eureka Network?
15:30-15:45	Break

Friday, 18th November 2022 (Continued)

Time	Title & Speakers
15:45-16:45	<p data-bbox="353 337 1095 373">The Journey is the Destination (Remote Session)</p> <p data-bbox="353 378 697 414">Speaker: Wong Tien Yin</p> <p data-bbox="353 450 482 485">Abstract</p> <p data-bbox="353 524 1921 1119">The career journey of the "academic clinician", whether it is a clinician-scientist or translational scientist, typically follows a pathway in three overlapping phases: Training, Consolidation, and Impact. During the Training phase, the person undergoes intensive graduate studies (e.g., PhD) and further training to hone his/her research skills (e.g., post-doc fellowships), with the main focus of the acquire depth and expertise, and skills in writing papers and grants. During the Consolidation phase, the person develops a focused research program with grants, papers and presentations, and aims for independence typically as an tenured Associate Professor. The last phase of Impact is longer and more complex and is determined by the person's career aspiration and "sweet spot" (the intersection of training, expertise and personal goals) The person may choose research leadership, continuing to build on his/her focused research program but with a larger team of post-docs and students and aims to be an international leader of that particular field. On the other hand, the person may choose administrative leadership (e.g., as Chair of Department or Vice-Chair of Research) in which case the focus is on developing others and supporting programs outside of his/her area; "softer" skills in cultural sensitivity, people and systems management, business and political acumen are needed. In different phases, personal and family choices and sacrifices are inevitable. This talk will cover some of these skills with lessons gleaned over 20+ years in academia working in the four countries: US, Australia, Singapore and China. The journey itself is the destination.</p> <p data-bbox="353 1160 656 1196">Learning Objectives</p> <ol data-bbox="353 1237 1804 1421" style="list-style-type: none"> 1.Appreciate the different "phases" of an academic and scientific career in medicine, biotechnology and healthcare 2.Understand necessary ingredients of success in different "phases" 3.Review personal goals, motivations and aspirations, to make considered career decisions in different "phases" understanding pros and cons of different choices. <p data-bbox="353 1462 850 1498">Preparations (Reading Materials)</p> <ol data-bbox="353 1539 1902 1909" style="list-style-type: none"> 1.McKinney RE Jr. The Daunting Career of the Physician-Investigator. Acad Med. 2017 Oct;92(10):1368-1370. doi: 10.1097/ACM.0000000000001869. PMID: 28767494. 2.Weggemans MM, van der Schaaf M, Kluijtmans M, Hafler JP, Rosenblum ND, Prakken BJ. Preventing Translational Scientists From Extinction: The Long-Term Impact of a Personalized Training Program in Translational Medicine on the Careers of Translational Scientists. Front Med (Lausanne). 2018 Nov 9;5:298.doi: 10.3389/fmed.2018.00298. PMID: 30474027; PMCID: PMC6237913. 3.Stoller JK. Developing physician-leaders: a call to action. J Gen Intern Med. 2009 Jul;24(7):876-8. doi: 10.1007/s11606-009-1007-8. Epub 2009 May 20. PMID: 19455370; PMCID: PMC2695517. <p data-bbox="353 1950 1050 1986">Pre-Session Thought Questions for Participants</p> <ol data-bbox="353 2027 1590 2211" style="list-style-type: none"> 1.Where are you at the different stages of your career (Training, Consolidation, Impact)? 2.What is your immediate (1-3 year) goals? 3.What is your longer term (5-10 years) career aspiration 4.What are your strengths and weaknesses 5.Who are your role models?
16:45-17:00	Closing Remarks
17:00	Day Ends



Faculty Biographies



**Salvatore Albani, MD, PhD**

My field of research is to understand and manipulate human immunity to ultimately and tangibly improve Health. I have developed a comprehensive technology platform which pivots on high dimensionality approaches, including cytometry, 10X single cell next generation RNA sequencing and in vitro functional modelling. We have developed Artificial Intelligence (AI) tools to distill mechanistically and clinically relevant knowledge from the interfaces among these high complexity datasets and the clinical data. By leveraging on this platform, validated predictive modelling is developed. This platform enables fundamental progress in several translationally relevant, first in class scientific contributions, which span across disease areas ranging from Autoimmunity to Cancer. It is important to emphasise the unifying conceptual framework to conceive mechanistic and therapeutic manipulations of the human immunome not as an intervention on discrete pathways which stand isolated and can be switched on and off, but rather as the sophisticated manipulation of a gradient of pathways and cell subsets which are inextricably inter-laced, and can be modulated within a continuum of intensity, comparable to what a rheostat does to the intensity of lighting in a room. I look at the architecture of the Immune System and its therapeutic manipulation by evolving from fragmentation to a continuum gradient balanced on homeostasis and tilted by perturbations such as disease or even conventional therapy.

My contribution is to have conceived and evolved this concept to tangible applications. Each of the projects can bring a solution to unmet needs. Combined, the platform advances Science by looking holistically and with high dimensionality at mechanisms of immune imbalances, thus leading to the identification of novel immune therapeutic targets which we are developing for restoration of immune homeostasis. Some of the most advanced projects include:

- 1) Defining for the first time an AI-driven, high dimensional architecture of the healthy Immunome (EPIC), and assessing the effects of Disease as perturbations of this architecture;
- 2) Conceiving and developing Chimeric Antigen Receptor Treg (CARTreg) as an entirely novel approach to cellular immunotherapy of transplant rejection, graft versus host disease and systemic autoimmunity;
- 3) Conceiving and developing new composition of matter and next steps for the development to commercial fruition of a Phase IIb – ready, first in class immunotherapy for Rheumatoid Arthritis;
- 4) A theragnostic platform to predict the opportunity to withdraw patients with arthritis from biologics. My work has been published in most relevant Journals of high calibre (IF of 49 and 8802 citations), and generated a diverse portfolio of more than 100 patents. This work is the foundation of my entrepreneurial activities, currently pivoted on Ananda Immunotherapies, PTE LTD, of which I am the scientific Founder and Chairman.

I am very active in education. Indeed, a most rewarding part of my professional life is to infect others with my passion for what I do, and to share my experiences, my successes and my failures. I am the co-founder and President of the Eureka Institute for Translational Medicine, an international organisation focused on the advancement of Translational Medicine through research, education and policy shaping.



Scott Compton, PhD

Professor Scott Compton is the Associate Dean for Medical Education and the Programme Director for the Duke-NUS Master of International Translational Medicine (MITM) degree programme. He is also a member of the Eureka Institute for Translational Medicine. As a researcher, Professor Compton has focused his efforts on improving outcomes from out-of-hospital cardiac arrest, enhancing palliative emergency medicine, and improving medical education. He has an established mentor and educator, having been recognised for his teaching at every level of the educational spectrum and has been awarded the Golden Apple Award for Generativity for Educators from the Academic Medicine Education Institute of Duke-NUS / SingHealth Academic Medical Centre.



Muhammad Raihan Jumat, PhD, Fellow (HEA)

Dr Raihan Jumat is an educationalist with a background in molecular virology. As a newly appointed faculty member at Duke-NUS, Raihan oversees the Master's in Translational Medicine program. Raihan facilitates learning amongst students and the diverse panel of faculty over the 2-year course. He trained in Team-based Learning and has designed and taught undergraduate as well as post-graduate classes according to evidence-based principles. While initially focused on respiratory viruses and environmental microbiology, Raihan's research interests now include burnout in medical students and digital tool usage amongst faculty. As an educator, Raihan promotes open and frank conversations on learning and fostering the exchange of ideas and synthesis of novel concepts.



Adrian Lim, BCom/LLB, MBA

Adrian is the CEO and co-founder of Ananda Immunotherapies, a smart biotech (imminently coming out of stealth) developing next generation approaches against immune mediated disease.

Adrian has an international commercial background and worked for many years at global management consulting firm L.E.K. Consulting, in the firm's offices in Australia and later in the US and in Japan. There he advised clients across a range of sectors, including media, transport and healthcare & life sciences. Adrian was also closely involved in the firm's Asia Pacific HR function, across recruitment, team onboarding and talent development in Singapore, India and Australia. Adrian co-founded his first biotech company in 2014, focused on a clinical-stage peptide-based candidate for treating inflammation linked diseases. There he ran commercial operations including team development, partnerships, finance and intellectual property.

Adrian has an MBA from INSEAD, France/Singapore, and a Bachelor of Commerce (economics & finance), Bachelor of Laws, and a Diploma in Modern Languages (Japanese) from the University of Melbourne, Australia.



Ann-Marie Chacko, PhD

As an Assistant Professor in the Duke-NUS Programme in Cancer and Stem Cell Biology, and Head of the Duke-NUS Laboratory for Translational and Molecular Imaging (LTMI), Prof Ann-Marie Chacko work to combine molecular imaging efforts in drug discovery and early drug development. Through academic and industrial collaborations through Duke-NUS' world-class research programs, she lead the translational efforts for a portfolio of in vivo PET, SPECT, CT and optical imaging agents that span key therapeutic areas including oncology, immunology, infectious disease and neurobiology.

She currently leads a national initiative, the Cancer ImmunoTherapy Imaging (CITI) Programme, which received a S\$22M Singapore Health and Biomedical Sciences (HBMS) Industry Alignment Fund Pre-Positioning (IAF-PP) grant in late 2018. This initiative aims to address the urgent call for biomarker-driven approaches to monitor tumour immune responses, leveraging on the expertise of its strong multidisciplinary team across 12 research organisations in Singapore and four research themes: Immunology, Chemistry, Imaging, and Clinical Trials.

Prof Chacko is committed to educating a new generation of scientists and clinician-scientists, through outreach, teaching, and mentorship. In particular, she leads the SingHealth Duke-NUS Women in Science (WinS) Network to support the professional development of female research scientists and clinician-scientists across all professional and training levels. Her flag-ship effort is the Career Advancement Programme (WinS-CAP) for early career scientists, providing in-depth training workshops, and faculty-peer mentor sessions to address some of the unique challenges faced by women scientists.



Ang Hwee Ching, PhD

Dr. Hwee Ching Ang (洪慧菁), is Deputy Chief Executive Officer (DCE) at EDDC. She was previously acting COO of NTUitive, the innovation and enterprise company of the Nanyang Technological University, Singapore (ranked World's Top Young University, 2013-2018 by QS).

Prior to this, she was Head of Bayer's Innovation Centre Singapore, where she was part of the Global External Innovation and Alliances team and responsible for partnering activities in Asia Pacific (excluding China, Japan). Before joining Bayer in 2011, Dr. Ang was Deputy Director at the Biomedical Sciences Industry Partnership Office, a multi-agency office set up to work with biomedical sciences companies and drive partnering activities with Singapore institutions.

Over the years, Dr. Ang has set up and managed a number of public-private research partnerships from both academic and industry sides. She was previously responsible for Business Development, Project Management and Alliance Management at the Lilly Singapore Centre for Drug Discovery and at the A*STAR Experimental Therapeutics Centre where she was part of the start-up team led by Prof. Sir David Lane. She has also worked on strategic initiatives to build the Singapore biomedical industry and was part of a team evaluating grant and equity support for biotech companies while at the Singapore Economic Development Board.

Hwee Ching completed her undergraduate studies in Chemical Engineering and Finance, and a master's degree in Biotechnology at the University of Pennsylvania (US) and her Ph.D. studies with Prof. Sir Alan Fersht at the MRC Centre for Protein Engineering at Cambridge University (UK).



Berent Prakken, MD, PhD

Berent Prakken (MD, PhD) is vice-dean and director of the biomedical education centre at the University Medical Center Utrecht (UMCU), the Netherlands. He is also professor of paediatric immunology at the UMCU and honorary professor at the University of Ghent, Belgium. Berent Prakken has built a translational research lab that focused on regulation of inflammation and biomarker development in human in inflammatory diseases. He received numerous national and international awards and grants for his work. The work of his group is published in all major international journals, including Nature Medicine, PNAS, Immunity, the Lancet, JCI and in various Nature journals. Over the years he successfully mentored more than 40 PhD students. Prakken serves in various national and international research advisory boards and was member of the Dutch National Health Council ('Gezondheidsraad'). He was vice-chair of Medical Ethical Review Board (IRB) of the UMCU. Berent Prakken is president of the Paediatric Rheumatology European Society (PRES) and member of the EULAR executive committee. He is member of the steering committee of UCAN (international federation facilitating biological research in arthritis) and has set up the first international platform for biological studies in arthritis (UCAN-U, www.ucan-u.org).

Berent Prakken's personal commitment is to training & education and to improve the impact of science. Unconventional thinking, collaboration and crossing boundaries inspire him, just as his close friendship with Salvo Albani, Norm Rosenblum and the other board members of Eureka. As co-founder and board member he enjoys the journey on which Eureka is taking them.



Chriscavin Wijaya

Chriscavin is a 24 year old Indonesian who was diagnosed with High-Risk Acute Lymphoblastic Leukaemia in December 2013 at the age of 15. He had two relapses in 2015 and 2017 and was the first patient to receive CAR-T Cell Therapy in Singapore in March 2018. He completed his Higher Diploma in Media and Mass Communications in June 2020 and has been volunteering at several foundations whilst preparing to pursue further education.



Danny Soon, MBBS

Assoc. Prof. Danny Soon is Chief Executive Officer at the Consortium for Clinical Research and Innovation, Singapore (CRIS) and concurrent Executive Director at the Singapore Clinical Research Institute (SCRI). As the inaugural CEO, Danny has the responsibility of bringing together five research programmes and platforms under the auspices of CRIS, promulgating synergies and strategies, building corporate functions to service the entire entity.

Danny was previously the Executive Director of Biomedical Research Council (BMRC) in A*STAR. His team in BMRC was responsible for incepting and coordinating efforts and programmes in drug development, precision medicine, medical technology and biomanufacturing. Previously, Danny also held the role of founding and Acting CEO of the Experimental Biotherapeutics Centre. In this role, where he and his team were responsible for setting up a brand new centre for biotherapeutics development.

Danny has long experience in drug development, having worked at Eli Lilly and Company for 15 years, where he headed up the Lilly-NUS Centre for Clinical Pharmacology (LNUS). As the Managing Director and Principal Investigator, Danny had responsibility and oversight for all clinical Phase 1 studies conducted and operations in the unit. Studies conducted included first-in-human studies, biomarker development work, human physiology investigations and pivotal registration PK studies, in neuroscience, diabetes, musculoskeletal and cardiovascular therapeutic areas.



David Wang Xinyuan, MD, MBA

David Wang is the Director of Centre of Technology Development at Duke-NUS. David has years of experiences in intellectual property management, technology acceleration and commercialisation, and new ventures. From 2017 to 2020 David was a Senior Acceleration Manager at Innovation Ventures of Cincinnati Children's, an international leader in paediatric medicine, research and education. He led the assessment, identification, acceleration management of Cincinnati Children's most promising biomedical programs, resulting in translational value creation and closure of massive transactions in licensing, product co-development, and venture investment. Prior to joining Cincinnati Children's, David founded a life science company and secured \$6 million venture funding for the company. As the company founder, he managed whole cycle of product development and translated pioneering concepts into FDA-approved proprietary products. Previously, David worked for a number of years as a senior innovation manager at Cleveland Clinic, as a license manager at the University of Rochester, and as a drug discovery scientist at Pfizer. David received Bachelor (MBBS) and Master of Medicine from Hunan Medical University in China, and MBA from the University of Michigan. David has catalysed the translation of innovations into real world solutions for unmet biomedical needs, led and provided expert advising and coaching to innovators over the total product life cycle, created start-up ventures, raised first seed capital, and led to rounds of venture capital and corporate partnerships. David has negotiated and completed numerous transactions in licenses, options, product co-development, and seed/venture investments. David received 2020 Educational Institution and Federal Laboratory Partnership Award for his outstanding works in technology transfer and management of collaboration between Cincinnati Children's and NIH. David secured Certified Licensing Professional (CLP) designation in 2021.



Derrick Chan Wei Shih, BMedSci, BMBS, MCI, MRCPCH, CSCN, FAMS

Derrick Chan is Senior Consultant of Paediatric Neurology at KK Women's and Children's Hospital, Singapore. He received his medical degree from Nottingham University, U.K., and a Masters in Clinical Investigation in NUS, Singapore. He trained in Great Ormond Street Hospital and the Royal Children's Hospital in Melbourne in paediatric neurology and EEG and a Paediatric Epilepsy Fellowship at the Hospital for Sick Children in Toronto, Canada. He set up the paediatric comprehensive epilepsy programme for the systematic evidence-based evaluation, investigation and management of children with seizures, including epilepsy surgery, the ketogenic diet and vagus nerve stimulator at KKH. He has published on the epidemiology of seizures and epilepsy in children and paediatric electroencephalography in epilepsy. He was a pioneer recipient of the A*STAR BioEngineering Programme grant and developed computer vision-based seizure detection systems in conjunction with A*STAR Institute of Infocomm Research (I²R). He set up, led and published a study on the relationship of HLA*B1502 alleles with carbamazepine in severe cutaneous drug reactions in the Singapore paediatric population. He holds research grants in cost containment and implementation in epilepsy pharmacogenomics and is developing a commercial HLA-B*1502 testing kit together with A*STAR Institute of Materials Research and Engineering (IMRE) and NanoBioLab. He led the development of SG-Inspire, a ventilator for pandemic and resource-limited settings, which received 4 grants and broad media coverage. His NMRC CSA work on translational immunology in epilepsy with SingHealth Duke NUS Translational Immunology Institute was published in Nature Neuroscience. He leads the Clinician Innovator Development Programme at Duke-NUS Academic Development Department in the Office of Academic and Clinical Development.



Enny Kiesworo, BSc (Pharmacy), MHA, MSc (HPPF)

Enny's responsibilities span from developing research strategies, supervising the management of research project grants, ensuring financial sustainability & strategic management of research core platforms and strategic programs at SingHealth, to facilitating multi-institutional research collaborations across SingHealth institutions with external collaborator(s). As part of her responsibility, Enny oversees the management of SingHealth's technology transfer office, animal ethics secretariat, and compliance to research regulatory such as Personal Data protection. As one of the driver in the development of Academic Medicine Research Institute (AMRI) - *an innovative formation which brings together various functions of research in SingHealth and Duke-NUS*. Enny plays a critical role in supporting the development of researchers and research support staff careers within the SingHealth Duke-NUS Academic Medical Centre.

Enny obtained her Pharmacy Degree before furthering her study by pursuing a Masters in Health Administration (MHA) in Tulane University, USA under USAID's Scholarship, and another Masters in Health Policy, Planning and Financing (HPPF) in London School of Economics & Political Sciences and London School of Hygiene and Tropical Medicine under British Chevening Award.

Her professional background covers various aspects of biomedical and health care systems, spans from being a Hospital Consultant with a US healthcare group - National Medical Enterprises, Inc in Singapore -, Business Manager in-charged for Pre-Analytical Solutions and Diagnostics Business with Becton Dickinson (Indonesia and Singapore), to Hospital Operations (managing outpatient and inpatient operations, facility and programs expansion, fund raising, public education and various corporate functions of The Cancer Institute (the previous name of NCIS@NUHS) and management of multi-site clinical trials at Singapore Clinical Research Institute.



Francesco Caruso, LL.M, MSc

Francesco is the Head of the Firetree Group (www.firetree.org). As such he both manages the group's assets and oversees its philanthropic giving. He currently lives in Singapore with his wife.

Prior to establishing Firetree, Francesco was for over 10 years the executive director and ultimately executive chairman of the Richard P. Haugland Foundation, a US private foundation, which he dissolved in 2018 to settle the Firetree Trust in Singapore. Francesco is a founder and director of the newly created Asia Community Foundation in Singapore.

Francesco spends significant time on the road, working with the management of local organisations managed or supported by Firetree and has sat on the Board of various non-profits, including Angkor Hospital for Children in Cambodia, where he led the complete restructuring of the organisation in 2012. Before moving to Hong Kong in 2008, Francesco lived for five years in Cambodia where he co-founded M'Lop Tapang, a project for street children that currently serves several thousand children and youth in Sihanoukville.

Previous to his work with non-profit institutions, Francesco worked in finance and business development in North America and Europe. He holds a LL.M degree (International Law) and a Master Degree in Management.



Joanne Ngeow Yuen Yie, MBBS (Melb), MMed, FRCP (UK), FAMS, MPH

Associate Professor Joanne Ngeow, is a Senior Consultant in Division of Medical Oncology at the National Cancer Centre Singapore (NCCS). Assoc Prof Ngeow currently heads the NCCS Cancer Genetics Service with an academic interest in hereditary cancer syndromes and translational clinical cancer genomics. Her current clinical focus and research revolves around understanding cancer predisposition by studying cancers clustering in families, young adults and in families with multiple / rare cancer presentations. After completing her undergraduate medical studies at the University of Melbourne, Australia, in 2001, she completed her Internal Medicine training at the Singapore General Hospital and trained in Medical Oncology at NCCS. She was awarded consecutive fellowships by the SingHealth Research Foundation, National Medical Research Council and the Ambrose Monell Foundation to complete formal clinical and bench training as the Ambrose Monell Cancer Genomic Medicine Fellow at the Genomic Medicine Institute, Cleveland Clinic, Ohio. In 2015, she completed her Masters of Public Health at the Bloomberg School of Public Health, Johns Hopkins University, with a focus in cancer epidemiology and health economics making her one of a handful of individuals globally with skills spanning translational science, clinical genetics and health services research.

In 2018, Assoc Prof Ngeow joined Lee Kong Chian School of Medicine as Associate Professor while continuing to lead the clinical cancer genetics service and research programme in inherited cancer syndromes at NCCS. Assoc Prof Ngeow has published over 150 peer reviewed papers in such journals as the Journal of Clinical Oncology, Annals of Oncology, Human Molecular Genetics, Journal of Clinical Endocrinology and Metabolism, Gastroenterology. She is an Associate Editor for Endocrine-Related Cancers and Human Molecular Genetics. Her interests outside of academic medicine includes Asian art history, pottery and painting.



John C W Lim, MBBS, MSc, SM

Professor John CW Lim is founding Executive Director of the Centre of Regulatory Excellence (CoRE) at the Duke-National University of Singapore Medical School (Duke-NUS), inaugural Chairman of the Consortium for Clinical Research & Innovation Singapore (CRIS), Senior Advisor at Singapore's Ministry of Health (MOH), and Policy Core Lead at the SingHealth Duke-NUS Global Health Institute (SDGHI). He is Professor of Practice at Duke-NUS and the NUS Saw Swee Hock School of Public Health.

Formerly Chief Executive Officer of Singapore's Health Sciences Authority and Deputy Director of Medical Services (Industry & Research Matters) in MOH, Professor Lim has also held other senior positions in Singapore's Health and Education ministries. His current roles promote capacity building and scientific excellence for health products regulation, health policies and systems in Southeast Asia and the Asia-Pacific.

Professor Lim is a member of the Singapore Food Agency Board, APEC Life Sciences Innovation Forum's Executive Board, Davos Alzheimer's Collaborative Leadership Group, US Pharmacopoeia (USP) Council of the Convention as Asia-Pacific Chapter Chair, USP Quality Institute's Advisory Group, Centre for Innovation in Regulatory Science's Scientific Advisory Council, and St Andrew's Mission Hospital Board.

In 2018, Professor Lim received the Drug Information Association's Global Connector Inspire Award for leadership in promoting global collaboration to advance healthcare products to patients, and the Regulatory Affairs Professional Society's highest Founder's Award recognising substantial sustained impact in shaping regulatory practice and policy over the course of his career.



Mara McAdams, MD

Dr McAdams received her Bachelor's Degree with Distinction in History of Art from Yale University before attending New York University for medical school. She completed her residency training in Internal Medicine - Primary Care at Bellevue Hospital, New York City's largest public hospital, developing her clinical acumen alongside knowledge and skills in medical education. After receiving her board certification in Internal Medicine, she moved to Singapore.

Dr McAdams joined Duke-NUS, a graduate medical school collaboration between Duke University and National University of Singapore as a founding member of the teaching faculty when it launched in 2007.

At Duke-NUS, Dr McAdams created and grew the Standardised Patient (SP) Programme, designed and ran the school's two clinical skills exams until 2013, and taught in the classroom-based doctoring and communication courses. In 2013, she was recruited to take on the role of Assistant Dean, Student Affairs and in 2016 she expanded her support and development portfolio in the school to include Alumni Relations. Currently, she is Associate Dean, Alumni Relations focusing on supporting alumni engagement and personal and professional development. She also leads the CARE 1 syllabus, a longitudinal curricular thread teaching emotional intelligence, team dynamics and adaptive resilience to students. She teaches resilience workshops for the Institute of Patient Safety and Quality and ran a series of Positive Psychology workshops for Duke-NUS and NUS alumni.



Ng Chirk Jenn, MBBS, MMed (Family Medicine), PhD

Prof Ng is a Senior Consultant at SingHealth Polyclinics, and a Clinical Professor at Duke-NUS Medical School. His research expertise is in the field of shared decision making, implementation science, digital health and men's health. He has collaborated with local and international clinicians, researchers and industry partners to develop, evaluate and implement digital health and e-learning solutions including patient decision aids, screening health application for men, Covid-19 symptom monitoring system and reusable learning objects. He was the Editor in Chief of Malaysian Family Physician, Deputy Dean (Research) Faculty of Medicine, University of Malaya and Deputy Chair, Medical Research Ethics Committee, University of Malaya Medical Centre before his relocation to Singapore in 2021.



Ronne Yeo, PhD

Dr. Ronne Yeo is a biotech investor, inventor and entrepreneur with a track record in leading R&D in a biotech company. Ronne joined Esco Ventures in 2016, the corporate investment arm of Esco Group and predecessor of EVX Ventures, and has since been identifying and evaluating investment opportunities in innovative drugs. Ronne played key roles towards developing EVX Ventures' capabilities in biotech venture creation. Working alongside XQ Lin and leveraging his scientific training in extracellular vesicles, he became a key founding member for Carmine Therapeutics, EVX Ventures' flagship company and first to expand R&D operations into Boston MA. Carmine is pioneering non-viral gene therapy based on red blood cell extracellular vesicles, with Professors Harvey Lodish, Minh Le and Jiahai Shi as scientific co-founders. As Founding Vice President of Discovery, Ronne built and led the R&D team to create the Red Cell EV Gene Therapy (REGENT™) Platform to enable targeted delivery of large, complex nucleic acid cargoes, leading to a research collaboration with Takeda Pharmaceuticals in a deal worth over USD 900M, in a span of a little over a year since its founding. Carmine went on to become named as one of FierceBiotech's "Fierce 15" companies of 2020, designating it as one of the most promising private biotechnology companies in the world. Ronne continued his role as head of R&D supervising research in both the US and Singapore sites until November 2021 when he moved on to a new EVX Ventures portfolio company, Carcell Biopharma, as cofounder and Chief Scientific Officer. During his stint at Carmine, Ronne was the inventor of key patent families and several know-hows that underlie its non-viral gene therapy programs. Ronne conceptualised and pioneered EVX Ventures' initiatives to ensure a proprietary deal-flow for investment or company creation. These are the Morphosis Fellowship program founded in 2018 and the PLATINUM grant launched in 2020.

Prior to joining EVX Ventures, Ronne was Senior Research Fellow at A*STAR Institute of Medical Biology, where he was involved in the preclinical development of mesenchymal stem cell extracellular vesicles - a novel therapeutic modality targeting cardiovascular and immune disorders, currently being developed by A*STAR spin-off Paracrine Therapeutics. Ronne obtained his PhD from NUS Graduate School - Integrative Sciences and Engineering Program (ISEP), and a BSc in Biological Sciences from Nanyang Technological University.



Sarada Bulchand, PhD

Assist Professor Sarada Bulchand is a scientist-educator. She holds a diverse portfolio in education, and learning & development. She leads the Duke-NUS Career Development Program for students and postdoctoral fellows, and conducts faculty development training for healthcare educators at the Duke-NUS SingHealth Academic Medical Centre.

She received her PhD from NUS in Molecular Biology and was a recipient of the Singapore Millennium Foundation Fellowship. Her postdoctoral work at Duke-NUS was on obesity induced insulin resistance.

She is a certified career coach and is also certified in Team Based Learning and Cognitive Behavioural Therapy. She has served as guest faculty at Mumbai University and has led the Science Communication Office at the Tata Institute of Fundamental Research, Mumbai. She aims to blend her extensive research experience with innovative areas of education and adult learning theories to foster life-long learning.



Soo Khee Chee, MBBS, MD, FRACS, FACS, FAMS

Dr Soo is a surgical oncologist, and Head and Neck surgeon. He was Head of Department of General Surgery at Singapore General Hospital for 11 years and was also the founding director of National Cancer Centre. His research interest is focused on Biphotonic and running phase 3 clinical trials. Currently he is the Principal Investigator of a clinical trial involving 12 different countries and the trial is to be completed in the next few months. He was the Deputy CEO in charge of research and education at the SingHealth Duke-NUS Academic Medical Centre.



Toh Han Chong, BSc (London), MBBChir (Camb), MRCP (UK), FRCP(Edin) FAMS

Dr Toh Han Chong is Senior Consultant and former Head at the Department (now Division) of Medical Oncology and now Deputy CEO (Strategic Partnerships), National Cancer Centre Singapore. He is a recipient of National Senior Clinician Scientist Award in 2017 and National Medical Excellence Award (NMEA) in 2018 for his pioneering work in cell and immunotherapy for cancer. Dr Toh leads the NMRC LCG VICTORY (Virus-Induced Cancers Translational Oncology and immunology) grant. He is the first in Singapore and in the region to establish a structured cancer immunotherapy programme over 15 years ago delivering on multiple completed and ongoing clinical trials (including first-in-human trials), comprising allogeneic blood stem cell transplantation, cancer vaccines, T cell therapy and immune checkpoint inhibitor studies. He has a strong, active interest in the translational biology and drug development for gastrointestinal cancers including colon and liver cancer.



Valerie Chew Suk Peng, PhD

Dr. Chew graduated with a PhD in immunology from Agency of Science, Technology and Research (A*STAR) Graduate Scholarship program in Singapore. Dr Chew then started her postdoctoral training in Singapore Immunology Network (SIgN), A*STAR focusing on tumour immunology. Since 2015, Dr Chew joined Translational Immunology Institute (TII), SingHealth Duke-NUS to advance her professional career in tumour immunology research. She also holds assistant professor position with Duke-NUS Medical School.

Dr Chew is the key researcher leading the project on understanding the impact of tumour immune microenvironment on clinical outcome in patients with hepatocellular carcinoma (HCC). Her work has gained recognition with multiple grant awards and high impact journals including Gut, Journal of the National Cancer Institute, Nature Genetics, and Journal of Hepatology.

Dr Chew is the key researcher leading the project on understanding the impact of tumor immune microenvironment on clinical outcome in patients with hepatocellular carcinoma (HCC). Her work has gained recognition with multiple grant awards and high impact journals including Gut, Journal of the National Cancer Institute, Nature Genetics, and Journal of Hepatology.



Wang Linfa, PhD

Linfa Wang is a professor of the Programme in Emerging Infectious Diseases at Duke-NUS Medical School, Singapore, and the executive director of PREPARE, Ministry of Health, Singapore. He is an international leader in the field of emerging zoonotic viruses and virus-host interaction. His current research focuses on why bats are such an important reservoir for emerging viruses and on how we can learn from bats to make us more resilience to infection and diseases in general. He is a member of the WHO SARS Scientific Research Advisory Committee and played a key role in identification of bats as the natural host of SARS-like viruses. In response to the COVID-19 pandemic, he has served/is serving on multiple WHO committees for COVID-19, including the WHO IHR Emergency Committee. Prof Wang has more than 500 scientific publications, including papers in Science, Nature, NEJM and Lancet. He is currently the Editor-in-Chief for the Virology Journal. Prof Wang was elected to the Australian Academy of Technological Sciences and Engineering in 2019 and the American Academy of Microbiology in 2021. He received the Singapore President Science Award in 2021.



Wong Tien Yin, MBBS, MMED, MPH, PHD, FRCSE, FRANZCO, FRCOPHT, FAHMS, FAMS

Prof Wong is an ophthalmologist and physician-scientist who completed medical school at the National University of Singapore (NUS) and a PhD from the Johns Hopkins University, USA. In 2022, he took up a new position as Chair Professor and Founding Head of Tsinghua Medicine at Tsinghua University, China. Over the past two decades, Prof Wong has served in multiple leadership positions in Singapore and Australia. His last position was Arthur Lim Professor and Medical Director of the Singapore National Eye Center, one of the largest tertiary eye-care hospital in Asia and globally. Prof Wong has also served as Chair of Departments of Ophthalmology at NUS and University of Melbourne, Australia.

Prof Wong is a retinal specialist, with a research portfolio on retinal diseases and ocular imaging, including AI. He has published >1,400 peer-reviewed papers (h-index 184), given >500 invited named, plenary, and symposium lectures globally, and received >US\$100 million in grant funding. Prof Wong has been recognised with multiple international awards, including Arnall Patz Medal (Macula Society), the Alcon Research Institute Award, the Jose Rizal Medal (Asia Pacific Academy of Ophthalmology). He has received Singapore's President's Science and Technology Award. He is an elected international (foreign) member of the US National Academy of Medicine.



Yeo Joo Guan, MBBS (S'pore), MMed (S'pore), MRCPCh (UK), PhD (S'pore)

Dr Yeo Joo Guan is a Senior Consultant in Paediatric Medicine at KK Women's and Children's Hospital. He earned his M.B., B.S. and Masters of Medicine (Paediatric Medicine) from the National University of Singapore (NUS) in the year 2000 and 2006 respectively. During his advanced speciality training, he obtained his PhD from the Department of Microbiology, Immunology programme, NUS, on the role of serine protease C1s in lupus pathogenesis supported by the Ministry of Health's Healthcare Research Scholarship in 2014.

Following the completion of his advanced speciality training in 2015, he was mentored by Professor Salvatore Albani (Translational Immunology Institute), working on the holistic, multi-dimensional interrogation of the immunome of childhood-onset Systemic Lupus Erythematosus with the dual translational goals of identifying predictors of clinical fate and novel therapeutic targets for manipulation.

He is happily married with 6 children and has a supportive wife seeing him through his endeavour to become a successful clinician scientist with the hope of making a difference in improving the care of paediatric rheumatological patients through translational medicine.

In his free time, he is actively involved in organising outdoor scouting activities for children as a volunteer adult leader. He believed that influencing the next generation either through holistic education in non-academic skills, in addition to his work as a researcher are important life goals that are worth pursuing.

Course Curriculum

Time Starts	Monday, 14 Nov	Tuesday, 15 Nov	Wednesday, 16 Nov	Thursday, 17 Nov	Friday, 18 Nov
07:45	From Harbourfront MRT Station Exit D Taxi Stand; 7:00am slot 7:45am slot 8:10am slot 8:30am slot	From Harbourfront MRT Station Exit D Taxi Stand; 7:00am slot 7:45am slot 8:10am slot 8:30am slot	From Harbourfront MRT Station Exit D Taxi Stand; 7:00am slot 7:45am slot 8:10am slot 8:30am slot	From Harbourfront MRT Station Exit D Taxi Stand; 8:30am slot 8:45am slot 9:25am slot 9:45am slot	From Harbourfront MRT Station Exit D Taxi Stand; 7:00am slot 7:45am slot 8:10am slot 8:30am slot
08:30	08:30-09:00 Registration	08:30-09:00 De-briefing: What can you bring home	08:30-09:00 De-briefing: What can you bring home		08:30-09:00 De-briefing: What can you bring home
08:45		Speaker: Raihan Jumat	Speaker: Raihan Jumat		Speaker: Raihan Jumat
09:00	09:00-10:00 Introductions	09:00-11:15 (with 15' break) Drug Development	09:00-11:15 (with 15' break) The Foundation and the Future of Clinical Development		09:00-10:00 Journey into the future
09:15	Speakers: Raihan Jumat Scott Compton	Speaker: Salvatore Albani	Speakers: Danny Soon John CW Lim		Speaker: Ronne Yeo
09:30		10:00-10:15 Break	10:00-10:15 Break		09:55-10:00 Q&A Session
09:45		11:10-11:15 Q&A Session	10:00-10:15 Break	09:45-10:15 De-briefing: What can you bring home	
10:00	10:00-10:15 15-min Break		11:10-11:15 Q&A Session	Speaker: Raihan Jumat	10:00-10:15 15-min Break
10:15	10:15-11:15 Translational Medicine Overview			10:15-11:15 Philanthropic Funding	10:15-11:15 Mentoring Session 2
10:30	Speaker: Salvatore Albani			Speaker: Francesco Caruso	Mentors: Ann-Marie Chacko Enny Kiesworo Raihan Jumat Salvatore Albani Soh Khee Chee Yeo Joo Guan
10:45	11:10-11:15 Q&A Session			11:10-11:15 Q&A Session	
11:00					
11:15	11:15-12:15 Patient and Society	11:15-12:15 Culturally Competent Communication - Part 2	11:15-12:15 Finding a New Equilibrium	11:15-12:15 Mentoring Session 1	11:15-12:15 Protecting Intellectual Property
11:30	Speakers: Toh Han Chong Chriscavin Wijaya	Speakers: Mara McAdams Sarada Bulchand Scott Compton	Speakers: Mara McAdams Sarada Bulchand	Mentors: Ann-Marie Chacko Enny Kiesworo Raihan Jumat Salvatore Albani Soo Khee Chee Yeo Joo Guan	Speaker: David Wang Xinyuan
11:45	12:10-12:15 Q&A Session	12:10-12:15 Q&A Session	12:10-12:15 Q&A Session		12:10-12:15 Q&A Session
12:00					
12:15	12:15-13:30 Buffet Lunch @ Bar Nebula Level 1	12:15-13:30 Set Lunch @ Latitude Bistro	12:15-14:30 Buffet Lunch @ Bar Nebula Level 1	12:15-13:30 Set Lunch @ Latitude Bistro	12:15-13:30 5-Course Lunch @ WOK 15
12:30					
12:45					
13:00					
13:15					
13:30	13:30-14:30 Digital Health	13:30-14:30 Communication: Self-Awareness & Self-Management		13:30-14:30 Impactful Venture	13:30-14:30 Magic Bullet (3/3)
13:45	Speaker: Ng Chirk Jenn	Speakers: Mara McAdams Sarada Bulchand		Speaker: Arcot Desai Narasimhalu	Facilitators: Ann-Marie Chacko Raihan Jumat Salvatore Albani Scott Compton Yeo Joo Guan
14:00	14:25-14:30 Q&A Session	14:25-14:30 Q&A Session		14:25-14:30 Q&A Session	
14:15					
14:30	14:30-15:30 PREPARE	14:30-15:30 Presentation Workshop	14:30-16:30 Magic Bullet (1/3)	14:30-15:30 Magic Bullet (2/3)	14:30 - 16:30 Being an Eurekian - How to make an impact as an Eurekian?
14:45	Speaker: Wang Linfa	Facilitators: Ann-Marie Chacko Salvatore Albani Sarada Bulchand Scott Compton Raihan Jumat Yeo Joo Guan	Facilitators: Ann-Marie Chacko Raihan Jumat Salvatore Albani Scott Compton Sarada Bulchand / Yeo Joo Guan	Facilitators: Ann-Marie Chacko Raihan Jumat Salvatore Albani Scott Compton Sarada Bulchand / Yeo Joo Guan	Speakers: Ann-Marie Chacko Yeo Joo Guan
15:00	15:25-15:30 Q&A Session				15:25-15:30 Q&A Session
15:15					
15:30	15:30-15:45 15-min Break	15:30-15:45 15-min Break	15:30-16:45 15-min Break	15:30-15:45 15-min Break	15:30 - 16:45 15-min Break
15:45	15:45 - 17:45 Culturally Competent Communication - Part 1	15:45-16:45 Communication: Relationship Management	15:45-16:45 Career Trajectory Dissection (Online)	15:45-16:45 Inequalities & Inequities in Healthcare & Science	15:45 - 16:45 The Journey is the Destination (Online)
16:00	Speakers: Mara McAdams Sarada Bulchand Scott Compton	Speakers: Mara McAdams Sarada Bulchand	Speaker: Berent Prakken	Speakers: Ann-Marie Chacko Valerie Chew Suk Peng	Speaker: Wong Tien Yin
16:15	17:40-17:45 Q&A Session	16:40-16:45 Q&A Session	16:40-16:45 Q&A Session	16:40-16:45 Q&A Session	16:40-16:45 Q&A Session
16:30					
16:45		16:45-17:45 Speed Consulting 1	16:45-17:45 SG Startup Enterprise	16:45-17:45 Speed Consulting 2	16:45 - 17:00 Closing Remarks
17:00		Faculty: Ann-Marie Chacko Derrick Chan Wei Shih Joanne Ngeow Yuen Yie Raihan Jumat Salvatore Albani Sarada Bulchand Scott Compton Yeo Joo Guan	Speakers: Adrian Lim Salvatore Albani Ang Hwee Ching	Faculty: Ann-Marie Chacko Derrick Chan Wei Shih Raihan Jumat Salvatore Albani Sarada Bulchand Scott Compton Yeo Joo Guan	17:00 Day Ends
17:15					
17:30			17:40-17:45 Q&A Session		
17:45	17:45 Day Ends	17:45 Day Ends	17:45 Day Ends	17:45 Day Ends	